44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1 Non-GAAP Financial Measures This presentation includes the presentation and discussion of certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("U.S. GAAP"). These non-GAAP financial measures, including, but not limited to, adjusted EBITDA, free cash flow, free cash flow excluding transaction-related costs, and adjusted EPS, are presented in order to supplement inv ...

Core Insights - Viatris Inc. has appointed Lara Ramsburg as Chief People and Corporate Affairs Officer to enhance the company's culture and stakeholder communication strategies during its transformation efforts [1][5]. Company Overview - Viatris is a global healthcare company that aims to bridge the gap between generics and brand-name medications, providing access to high-quality medicines for approximately 1 billion patients annually [6]. Leadership and Experience - Lara Ramsburg brings over 25 years of experience in building effective cross-functional teams and strategic communication, having held various executive roles at Viatris and its legacy company, Mylan [2][3]. - In her new role, Ramsburg will oversee global talent, total rewards, employee experience, people solutions, and HR business partner teams, in addition to her existing responsibilities in Corporate Affairs [3]. Strategic Importance - The appointment of Ramsburg is seen as crucial for maintaining employee engagement, wellbeing, and growth as the company prepares for its next stage of growth [5].

Core Viewpoint - Viatris (VTRS) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the consensus measure of EPS estimates from sell-side analysts, reflecting the company's changing earnings picture [1][2]. - A strong correlation exists between earnings estimate revisions and near-term stock price movements, with institutional investors using these estimates to determine fair value [4][6]. Company Performance and Investor Sentiment - The upgrade in Viatris' rating signifies an improvement in the company's underlying business, which is expected to positively influence its stock price [5][10]. - Over the past three months, the Zacks Consensus Estimate for Viatris has increased by 2.2%, with expected earnings of $2.32 per share for the fiscal year ending December 2025, unchanged from the previous year [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - Viatris' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9][10].

Core Insights - Viatris Inc. (NASDAQ:VTRS) is recognized as one of the top cheap stocks under $20, with recent regulatory milestones enhancing its investment appeal [1] Regulatory Milestones - The FDA approved Viatris' octreotide acetate for injectable suspension, a generic version of Sandostatin® LAR Depot, for treating acromegaly and certain types of diarrhea associated with tumors [1] - The FDA accepted the New Drug Application (NDA) for Viatris' investigational low dose estrogen weekly patch for contraception [2] - The FDA cleared the Investigational New Drug (IND) application for MR-146, a gene therapy candidate for neurotrophic keratopathy, with plans for a Phase 1/2 clinical trial starting in H1 2026 [2] - The Japan Pharmaceuticals and Medical Devices Agency (PMDA) accepted the Japanese New Drug Application (J-NDA) for pitolisant in obstructive sleep apnea syndrome, with plans to submit a J-NDA for narcolepsy by year-end [3] Company Overview - Viatris is a global healthcare company providing a wide range of pharmaceutical products across various therapeutic areas, including oncology, cardiovascular, dermatology, immunology, eye care, gastroenterology, and women's healthcare [4] - The company's operations are segmented into Developed Markets, Greater China, JANZ, and Emerging Markets [4]

Core Insights - Viatris Inc. (NASDAQ:VTRS) is recognized as one of the 14 Best Pharma Dividend Stocks to Buy in 2026 [1] - Barclays initiated coverage of Viatris with an Overweight rating and a price target of $15, indicating improving investor sentiment in the pharmaceutical sector [2] - Viatris announced a definitive agreement to sell its equity stake in Biocon Biologics Limited for a total consideration of $815 million, which includes $400 million in cash and $415 million in newly issued equity shares [3] Company Overview - Viatris Inc. is a global pharmaceutical company that offers a diverse range of medicines, including generics, branded drugs, biosimilars, OTC products, and active pharmaceutical ingredients (APIs) [4]

Industry Overview - Drug pricing has become a significant pressure point for pharmaceutical companies in the U.S. as efforts to reduce consumer costs at pharmacies intensify [1] - The U.S. is the largest single market for drugmakers, with prices often nearly three times higher than in other developed countries, leading to a heavy reliance on American sales for revenue [2] - The Most Favored Nations pricing model proposed by Donald Trump aims to tie U.S. drug prices to the lowest levels paid by other wealthy countries, which could have a substantial impact on pharmaceutical companies' financials if widely implemented [3][4] Market Performance - The S&P 500 Health Care sector has increased by over 13% this year, with health-care companies leading in earnings beats during the third quarter of 2025, marking the strongest performance in over four years [5] - Analysts suggest that as drug pricing uncertainty begins to ease, attention will shift to how pharmaceutical companies adapt to the changing landscape [5] Company Highlights Viatris Inc. (NASDAQ:VTRS) - Viatris has a dividend yield of 3.87% and is among the best dividend stocks in the pharmaceutical sector [11] - Barclays initiated coverage of Viatris with an Overweight rating and a $15 price target, noting improving investor sentiment and easing pricing pressure [12] - Viatris announced a deal to sell its equity stake in Biocon Biologics for $815 million, which includes $400 million in cash and $415 million in equity shares, aimed at enhancing its portfolio and market access [13] Gilead Sciences, Inc. (NASDAQ:GILD) - Gilead has a dividend yield of 2.54% and is recognized as a strong dividend stock [15] - The company entered a three-year agreement with the U.S. government to lower drug costs, reinforcing its commitment to U.S. innovation and affordability [16] - Gilead plans to invest $32 billion in U.S.-based manufacturing and R&D over the next five years, expecting to generate $43 billion in economic value and create over 3,000 jobs [17] Amgen Inc. (NASDAQ:AMGN) - Amgen has a dividend yield of 3.05% and has outperformed the broader market, with its stock up more than 27% since the start of 2025 [19] - The company reported a 12% revenue increase to $9.6 billion in the third quarter, driven by strong sales of key products like Repatha and Tezspire, both up 40% year-over-year [20] - Amgen has consistently raised its dividend since 2011, with a forward yield of about 3%, significantly higher than the S&P 500 average of 1.2% [22]

Core Insights - The article reflects on the performance of Viatris (VTRS) shares, noting a disappointing trajectory since the 2019 merger, and raises questions about the company's future prospects as of early 2023 [1]. Group 1: Company Overview - Viatris has experienced a lackluster performance since its formation from a significant merger in 2019, prompting a reevaluation of its investment potential [1]. Group 2: Investment Opportunities - The article suggests that there are actionable ideas related to major corporate events such as earnings reports, mergers, and acquisitions, indicating potential investment opportunities for stakeholders [1].

Core Insights - Viatris Inc. (VTRS) has announced four significant regulatory achievements in its pipeline, highlighting its R&D progress for 2025 and its commitment to advancing its portfolio globally [2][9]. Regulatory Approvals - The FDA has approved Viatris' octreotide acetate for injectable suspension, a generic version of Sandostatin LAR Depot, which is used for treating acromegaly and certain types of diarrhea related to tumors [3][4]. - This approval marks VTRS' first injectable product utilizing microsphere technology and is the fourth injectable approval for the company in 2025, enhancing its generics portfolio with complex, high-value products [4]. - The FDA has accepted VTRS' new drug application (NDA) for a low-dose estrogen weekly contraceptive patch, aimed at women with a BMI below 30 kg/m², with a target action date set for July 30, 2026 [5][6]. - The patch delivers approximately 150 mcg of norelgestromin and 17.5 mcg of ethinyl estradiol daily, representing a new option for women seeking lower estrogen doses [6][7]. - The FDA has cleared an investigational new drug (IND) application for MR-146, a gene therapy candidate for neurotrophic keratopathy, with a phase I/II clinical trial planned for the first half of 2026 [8][9]. - Viatris has also received acceptance for its Japanese NDA for pitolisant in obstructive sleep apnea syndrome (OSAS), with plans to submit a separate NDA for narcolepsy by year-end [10][11]. Company Performance - Viatris has demonstrated strong performance over the past six months, with shares increasing by 34.6%, compared to the industry growth of 6.1% during the same period [12]. - The company's expansion in Emerging Markets and robust growth in Greater China are positively impacting sales, with new drug approvals expected to further enhance its portfolio [13].

Core Insights - Viatris Inc. has announced four significant regulatory milestones in its global pipeline, highlighting advancements in research and development throughout 2025 [1][6][14] Group 1: Regulatory Approvals - The U.S. FDA has approved the company's octreotide acetate for injectable suspension, a generic version of Sandostatin LAR Depot, for treating acromegaly and certain cancer-related symptoms [6][14] - This approval marks the fourth injectable FDA approval for Viatris in 2025, alongside iron sucrose, paclitaxel, and liposomal amphotericin B, showcasing the company's ability to navigate complex regulatory pathways [3][14] - The FDA has accepted the New Drug Application (NDA) for a low dose estrogen weekly patch for contraception, with a target action date of July 30, 2026 [6][14] Group 2: Pipeline Developments - The investigational low dose estrogen weekly patch is designed for women with a BMI below 30 kg/m², delivering approximately 150 mcg of norelgestromin and 17.5 mcg of ethinyl estradiol per day [4][7] - The planned 505(b)(2) NDA for the patch is supported by positive results from the Phase 3 Luminous Study, demonstrating a favorable efficacy and safety profile [5][14] - The U.S. FDA has cleared the Investigational New Drug (IND) application for MR-146, a gene therapy candidate for neurotrophic keratopathy, with plans to initiate a Phase 1/2 clinical trial in the first half of 2026 [6][9][14] Group 3: International Developments - The Japan Pharmaceuticals and Medical Devices Agency has accepted the Japanese New Drug Application (J-NDA) for pitolisant in obstructive sleep apnea syndrome, supported by positive Phase 3 data [6][11][14] - The Phase 3 trial for pitolisant showed statistically significant improvements in excessive daytime sleepiness compared to placebo, indicating its potential effectiveness [11][14]

Core Insights - Viatris Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9 a.m. PT / 12 p.m. ET [1] - A live webcast of the presentation will be available, along with an archived version for a limited time [2] Company Overview - Viatris is a global healthcare company that bridges the gap between generics and brand-name medications, aiming to address healthcare needs worldwide [3] - The company provides access to high-quality medicines for approximately 1 billion patients annually, covering a wide range of health conditions from birth to end-of-life care [3] - Viatris has a diverse portfolio of medicines and a unique global supply chain, with headquarters in the U.S. and global centers in Pittsburgh, Shanghai, and Hyderabad [3]